Indian court rejects Bayer appeal against generic Nexavar
This article was originally published in Scrip
Executive Summary
A division bench of the Delhi High Court has dismissed an appeal by Bayer in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer, Nexavar (sorafenib tosylate).